Zevra Therapeutics reports FY 2024 net loss of $105.5M; sells PRV for $150M, cash runway into 2029

ZEVRA THERAPEUTICS, INC.

FY 2024 net revenue $23.6M (record Q4 product revenue $10.2M from MIPLYFFA); net loss ($105.5M) vs ($46.0M) in 2023.
Entered asset purchase agreement to sell Rare Pediatric Disease PRV for $150M gross; expected net proceeds $148.3M.
Cash and investments $75.5M at Dec 31, 2024; with PRV sale, cash runway extends into 2029; no going concern disclosure.
MIPLYFFA commercial launch: 109 total prescription enrollment forms as of Dec 31; EU filing targeted H2 2025.
OLPRUVA added 4 new patients Q4; DiSCOVER trial (VEDS) enrolled 27 patients; strategic review for KP1077 ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.